Table 1 Patient characteristics
All Patients | Urinary L-FABP levels | P value | ||
|---|---|---|---|---|
≥ 4 μg/g creatinine | < 4 μg/g creatinine | |||
Patients, n | 24 | 5 | 19 | |
Follow-upa, days | 529 (351, 920) | 294 (280, 383) | 770 (403, 952) | 0.017 |
Follow-upb, days | 559 (351, 920) | 294 (280, 490) | 770 (403, 952) | 0.030 |
Men, n (%) | 24 (100) | 5 (100) | 19 (100) | – |
Age, years | 42 (37, 49) | 54 (39, 58) | 42 (36, 46) | 0.101 |
Duration of receiving TDF, weeks | 102 (38, 248) | 88 (49, 317) | 115 (38, 229) | 0.859 |
Key drug | 0.491 | |||
INSTI, n (%) | 12 (50) | 2 (40) | 10 (52) | |
PI, n (%) | 7 (29) | 1 (20) | 6 (32) | |
NNRTI, n (%) | 5 (21) | 2 (40) | 3 (16) | |
CD4 cell counts, cells/μL | 571 (380, 790) | 668 (529, 760) | 557 (380, 818) | 0.804 |
HIV-RNA level | 1.000 | |||
< 20 copies/mL, n (%) | 18 (75) | 4 (80) | 14 (74) | |
20–500 copies/mL, n (%) | 6 (25) | 1 (20) | 5 (26) | |
Prior AIDS-defining illness, n (%) | 4 (17) | 0 (0) | 4 (21) | 0.544 |
eGFR, mL/min/1.73 m2 | 82.5 (78.7, 85.4) | 80.5 (73.2, 85.4) | 82.5 (79.1, 85) | 0.414 |
Urinary β2MG level, μg/L | 234 (122, 374) | 344 (308, 957) | 203 (122, 340) | 0.214 |
Urinary L-FABP level, μg/g creatinine | 1.8 (1.0, 4.0) | 5.0 (4.4, 19.1) | 1.4 (0.9, 2.8) | 0.001 |
Haemophilia (+), n (%) | 0 (0) | 0 (0) | 0 (0) | – |
Diabetes mellitus (+), n (%) | 0 (0) | 0 (0) | 0 (0) | – |
Dyslipidaemia (+), n (%) | 2 (8) | 0 (0) | 2 (11) | 1.000 |
Hypertension (+), n (%) | 2 (8) | 1 (20) | 1 (5) | 0.380 |
HBV (+), n (%) | 2 (8) | 0 (0) | 2 (11) | 1.000 |
HCV (+), n (%) | 0 (0) | 0 (0) | 0 (0) | – |